The road to any drug approval is a long road. Consider CBAY as a recent example of pharma ups and downs. Dr. Patterson hinted several times that his difference of opinion with Cytodyn is he would focus on few indications rather than try to address so many at the same time. Of course, the latter is what NP is doing. Certainly, COVID-19 emerging out of nowhere made the approval path more complicated by adding yet another indication for this tiny company to handle simultaneously. I tend to agree with Dr. Patterson's approach but on the other hand these entries into other indications are adding to the knowledge about Leronlimab's MOA faster than would have happened otherwise. Think of all the data gathered in the EINDs, CD10, and CD12, and the papers that will result.

I remain patient because its unrealistic to think approvals will move quickly. I've held back funds and will add if the stock drops. I would expect a rise again as CD12 interim approaches.